Bifogade filer
SynAct Pharma comments on ownership changes in Bioinvest Aps
Kurs & Likviditet
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Small Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
SynAct Pharma AB (publ) ("SynAct") comments on changes in ownership of the company's largest shareholder Bioinvest Aps, which has been jointly owned by SynAct's current CSO Thomas Jonassen and former CEO Jeppe Øvlesen and his wife.
Thomas Jonassen and the Øvlesen family have decided to terminate the joint ownership in BioInvest Aps, which means that the ownership in SynAct Pharma will be divided.
"Jeppe and I have decided to split our joint holding company as Jeppe no longer has an active role in the company and the tax advantage of having a joint holding company is no longer relevant, following the latest investment round in SynAct Pharma. I will continue to own the shares through a subsidiary of my 100% controlled holding company TJ Biotech Holding Aps", says Thomas Jonassen, CSO of SynAct Pharma.
As of October 31, BioInvest Aps owned 3,531,644 shares, corresponding to 9.93% of the capital and votes in SynAct Pharma. Thomas Jonassen owned 61% of Bioinvest Aps before the split.
Thomas Jonassen
CSO, SynAct Pharma AB
Phone: +45 40 15 66 69
Email: TJ@synactpharma.com
Email: investor.relations@synactpharma.com